Trials / Completed
CompletedNCT02798120
P3 Long Term Safety Study of Once Daily SB204 in Acne
A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 601 (actual)
- Sponsor
- Novan, Inc. · Industry
- Sex
- All
- Age
- 9 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open label long-term safety (LTS) study to be conducted in approximately 600 subjects with acne vulgaris.
Detailed description
A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SB204 4% | Open label, topical SB204 4% |
Timeline
- Start date
- 2016-05-12
- Primary completion
- 2017-04-01
- Completion
- 2017-04-27
- First posted
- 2016-06-14
- Last updated
- 2023-05-12
- Results posted
- 2023-05-12
Locations
69 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02798120. Inclusion in this directory is not an endorsement.